 |
- Home
- Clinical Perspectives
- Business Perspectives
- Patient Care
- Learning
- Community
- Products
- Careers
- About Us
E-mail Alerts
RSS Feeds
SITE TOOLS
In an in-office procedure, the corticosteroid implant is placed in the vitreous cavity via a proprietary solid polymer delivery system (Novadur, Allergan), which enables the extended release of the drug. The treatment is expected to be available in the third quarter of this year. The efficacy of the implant was assessed in two multicenter, double-masked, randomized parallel studies involving approximately 1,300 patients. In each individual study and in a pooled analysis, time to achieve a ≥15-letter (three-line) improvement in best-corrected visual acuity (BCVA) cumulative response rate curves was significantly faster with the implant compared with sham (p <0.01). “In the clinical studies, 20% to 30% of patients suffering from this severe retinal condition experienced a three-line improvement in BCVA, with an onset of effect within the first 2 months following therapy,” said Scott Whitcup, MD, executive vice president, research and development, and chief scientific officer, Allergan. The duration of effect persisted approximately 1 to 3 months after onset. “This new therapy provides physicians with a meaningful advancement in treating RVO, offering a convenient option to patients through its unique extended delivery profile,” said Mark S. Blumenkranz, MD, professor and chairman, Department of Ophthalmology, Stanford University, Palo Alto, CA. |   Practice Tools Coding Counselor Simple and accurate ICD-9 code search. Start Here  Formulary Counselor Find health plan drug coverage in your area. Start Here  Patient Education Print customized patient education handouts. Start Here  Surgical Video Center On-demand surgery demos and presentations. Start Here    
|
